Ann Thorell
Director of Finance/CFO at SERES THERAPEUTICS, INC.
Net worth: 25 485 $ as of 2024-03-30
Profile
Ann Marella Thorell is currently the Director at Living Beyond Breast Cancer.
She is also an Independent Director at ESSA Pharma, Inc., a Director at ApcinteX Ltd., and the Chief Financial & Accounting Officer at Seres Therapeutics, Inc. Ms. Thorell's former positions include being the Chairman at Vallon Pharmaceuticals, Inc., the COO, CFO, Secretary & Executive Director at Realm Therapeutics Plc, a Director at Capella Bioscience Ltd.
and Z Factor Ltd., the CFO, Treasurer, SVP & Chief Accounting Officer at Evelo Biosciences, Inc., and the Chief Financial Officer at Palladio Biosciences, Inc. She has also served as the President of Thorell Consulting and as the Chief Accounting Officer at Centessa Pharmaceuticals Plc.
Ms. Thorell obtained her undergraduate degree from Lehigh University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ESSA PHARMA INC
0.01% | 2024-03-24 | 2,881 ( 0.01% ) | 24 460 $ | 2024-03-30 |
EVELO BIOSCIENCES, INC.
0.12% | 2023-11-26 | 22,778 ( 0.12% ) | 1 025 $ | 2024-03-30 |
Ann Thorell active positions
| Companies | Position | Start |
|---|---|---|
| ESSA PHARMA INC. | Director/Board Member | 2019-07-30 |
| SERES THERAPEUTICS, INC. | Director of Finance/CFO | 2024-03-24 |
ApcinteX Ltd.
 ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Director/Board Member | 2021-01-28 |
| Living Beyond Breast Cancer | Director/Board Member | - |
Former positions of Ann Thorell
| Companies | Position | End |
|---|---|---|
| EVELO BIOSCIENCES, INC. | Director of Finance/CFO | 2023-11-19 |
| GRI BIOPAR | Chairman | 2023-04-20 |
| CENTESSA PHARMACEUTICALS PLC | Comptroller/Controller/Auditor | 2022-07-30 |
Z Factor Ltd.
 Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Director/Board Member | 2022-07-30 |
Capella Bioscience Ltd.
 Capella Bioscience Ltd. Pharmaceuticals: MajorHealth Technology Capella Bioscience Ltd. develops medicines based on monoclonal antibodies to the next generation therapeutic targets in oncology and autoimmune disease. The company was founded by Steve Holmes in 2014 and is headquartered in London, the United Kingdom. | Director/Board Member | 2022-07-30 |
Training of Ann Thorell
| Lehigh University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| ESSA PHARMA INC. | Health Technology |
| SERES THERAPEUTICS, INC. | Health Technology |
| EVELO BIOSCIENCES, INC. | Health Technology |
| CENTESSA PHARMACEUTICALS PLC | Health Technology |
| Private companies | 8 |
|---|---|
Realm Therapeutics Plc
 Realm Therapeutics Plc Pharmaceuticals: MajorHealth Technology Realm Therapeutics Plc engages in the development of novel therapeutics. It focuses on the prescription treatments for immune mediated diseases in adults and children. The company was founded on April 21, 2006 and is headquartered in Malvern, PA. | Health Technology |
| Living Beyond Breast Cancer | |
Capella Bioscience Ltd.
Capella Bioscience Ltd. Pharmaceuticals: MajorHealth Technology Capella Bioscience Ltd. develops medicines based on monoclonal antibodies to the next generation therapeutic targets in oncology and autoimmune disease. The company was founded by Steve Holmes in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
Z Factor Ltd.
Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Health Technology |
ApcinteX Ltd.
ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Health Technology |
Thorell Consulting
 Thorell Consulting Miscellaneous Commercial ServicesCommercial Services Thorell Consulting provides business consulting services. The private company is based in New York. | Commercial Services |
Palladio Biosciences, Inc.
 Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Health Technology |
Vallon Pharmaceuticals, Inc.
 Vallon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA. | Health Technology |
- Stock Market
- Insiders
- Ann Thorell
